Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
|
|
|
immune system
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
|
|
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells
|
hematopoietic system
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
|
|
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells
|
cellular
|
|
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
|
mortality/aging
immune system
hematopoietic system
growth/size/body
mortality/aging
immune system
liver/biliary system
neoplasm
|
|
• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)
|
hematopoietic system
growth/size/body
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation
(11 available);
any
Cd19 mutation
(56 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Klrk1tm1Dhr mutation
(3 available);
any
Klrk1 mutation
(24 available)
|
|
|
neoplasm
|
N |
• mice are protected from Lmp1-driven lymphomagenesis
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation
(11 available);
any
Cd19 mutation
(56 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
|
|
|
mortality/aging
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
immune system
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
|
|
• impaired in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice
|
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
|
|
• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells
• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer
|
|
|
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17
• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells
• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer
|
|
|
• minor in T cells co-cultured with tumor or B cells
|
|
|
• minor in T cells co-cultured with tumor or B cells
|
hematopoietic system
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
|
|
• impaired in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at 6 to 12 weeks in the bone marrow
|
|
|
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
|
|
|
• in an in vitro tumor killing assay, CD4+ T cells exhibit reduced tumor killing compared with control cells
• however, CD4+ T cells exhibit normal prevention of tumor outgrowth in vivo and elimination of nontransformed L,p1+ B cells upon transfer
|
|
|
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17
• in vivo, CD8+ T cells exhibit reduced prevention of tumor outgrowth compared with control cells
• however, CD8+ T cell exhibit normal tumor killing in vitro and elimination of nontransformed L,p1+ B cells upon transfer
|
growth/size/body
|
|
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
|
cellular
|
|
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre/ERT2)Rsky mutation
(1 available);
any
Cd19 mutation
(56 available)
Gt(ROSA)26Sortm11(Lmp1)Rsky mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
|
|
|
immune system
|
|
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|
|
|
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
|
|
|
• massive expansion in tamoxifen-treated mice
|
|
|
• massive expansion in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
|
|
|
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro
|
hematopoietic system
|
|
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|
|
|
• CD19+ B cells in tamoxifen-treated mice
• B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
• however, cell counts return to baseline after 2 weeks and a second application of tamoxifen does not result in another wave of B cell expansion
|
|
|
• massive expansion in tamoxifen-treated mice
|
|
|
• massive expansion in tamoxifen-treated mice
|
|
|
• in tamoxifen-treated mice
• however, T cell numbers decrease 8 days after tamoxifen application
|
|
|
• vigorous degranulation when T cells from tamoxifen-treated mice are exposed to LMP1-transduced B cells in vitro
|
growth/size/body
|
|
• with B cell blasts outnumbering normal splenic B cells 20-fold in tamoxifen-treated mice
|
Analysis Tools